

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
METHODOLOGY	2
INTENDED AUDIENCE.....	2
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	4
 CHAPTER TWO: SUMMARY.....	 5
<i>SUMMARY TABLE GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i>	 5
<i>SUMMARY FIGURE GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, 2007–2014 (\$ MILLIONS)</i>	 6
SUMMARY (CONTINUED)	7
 CHAPTER THREE: OVERVIEW	 8
INTRODUCTION	8
OSTEOPOROSIS OVERVIEW.....	8
MEDICATION TREATMENT.....	9
CLASSIFICATION OF OSTEOPOROSIS DRUGS.....	9
Bisphosphonates.....	10
SERMs.....	10
PTHs.....	11
Calcitonins	11
HRTs	12
<i>TABLE 1 MARKETED OSTEOPOROSIS DRUGS</i>	13
<i>TABLE 1 (CONTINUED)</i>	14
DRUG DELIVERY METHODS	14
Oral Drugs	15
Injectable Drugs.....	15
Nasal Spray and Transdermal Drugs.....	16
DRUG DEVELOPMENT PROCESS.....	16
INDUSTRY PLAYERS	17
MAJOR DRUG MANUFACTURERS.....	18
SPECIALTY PHARMACEUTICAL COMPANIES.....	18
SMALLER COMPANIES.....	19
COMPETITIVE FACTORS	20
SIGNIFICANT TRENDS.....	21

GLOBAL AGING POPULATION AND INCREASING LIFE EXPECTANCY TO LEAD TO THE RISING PREVALENCE OF OSTEOPOROSIS.....	21
LAUNCH OF NOVEL MECHANISM DRUGS AND IMPROVED FORMULATIONS OF MARKETED DRUGS TO ENHANCE TREATMENT OPTIONS.....	21
PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS AND GENERIC DRUG LAUNCHES TO HINDER MARKET GROWTH	22
CHAPTER FOUR: DISEASE OVERVIEW	23
OSTEOPOROSIS OVERVIEW.....	23
OVERVIEW OF THE BONE.....	24
BONE STRUCTURE.....	24
BONE REMODELING.....	25
THE ROLES OF HORMONES IN BONE HEALTH.....	26
The Roles of Hormones ... (Continued).....	27
CLASSIFICATION OF OSTEOPOROSIS	28
WHO CLASSIFICATION	28
<i>TABLE 2 WHO CLASSIFICATION OF OSTEOPOROSIS</i>	29
PRIMARY VERSUS SECONDARY OSTEOPOROSIS	29
MAYO CLINIC CLASSIFICATION.....	30
<i>TABLE 3 MAYO CLINIC CLASSIFICATION OF OSTEOPOROSIS</i>	30
OSTEOPOROSIS CAUSES AND RISK FACTORS	30
DIAGNOSIS	31
OSTEOPOROSIS COMPLICATIONS.....	32
DRUG CLASSES APPROVED IN THE TREATMENT OF OSTEOPOROSIS.....	33
<i>TABLE 4 OSTEOPOROSIS DRUG CLASSES</i>	34
BISPHOSPHONATES	34
SERMS.....	35
PTHS.....	35
DABAS	35
CALCITONINS	35
HRTS	36
<i>TABLE 5 OSTEOPOROSIS DRUG CLASSES COMPARISON</i>	36
<i>TABLE 5 (CONTINUED)</i>	37
MEDICATION TREATMENT ALGORITHMS	37
FIRST LINE OF THERAPY	38
SECOND LINE OF THERAPY	38
THIRD LINE OF THERAPY	38
CHAPTER FIVE: PATIENT POPULATION ANALYSIS.....	39
OVERVIEW.....	39

<i>TABLE 6 OSTEOPOROSIS-RELATED FRACTURES BY PATIENT'S GENDER, 2006 (%)</i>	40
PATIENT POPULATION CHARACTERISTICS: U.S. AND CANADA.....	41
<i>TABLE 7 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: U.S. AND CANADA, 2010 (MILLIONS)</i>	41
U.S.....	42
<i>TABLE 8 PREVALENCE OF OSTEOPOROSIS IN THE U.S., AGE ≥ 65 YEARS, 2004 (%)</i>	42
<i>TABLE 9 U.S. OSTEOPOROSIS-RELATED FRACTURES, 2005</i>	43
CANADA.....	43
PATIENT POPULATION CHARACTERISTICS: EU.....	44
<i>TABLE 10 ESTIMATED OSTEOPOROSIS PATIENT POPULATION IN THE EU, 2009 (MILLIONS)</i>	44
GERMANY	45
FRANCE	46
ITALY	46
SPAIN	46
U.K.	46
<i>TABLE 11 U.K. OSTEOPOROSIS-RELATED FRACTURES, 2005</i>	47
<i>TABLE 12 NUMBER OF HIP FRACTURES PER YEAR IN EU COUNTRIES, 2005</i>	47
PATIENT POPULATION CHARACTERISTICS: ROW	48
<i>TABLE 13 ESTIMATED OSTEOPOROSIS PATIENT POPULATION: SELECTED COUNTRIES IN THE ROW, 2009 (MILLIONS)</i>	48
CHINA	49
INDIA	49
JAPAN	49
LATIN AMERICA	50
CHAPTER SIX: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS.....	51
INDUSTRY STRUCTURE	51
TIERS OF COMPETITION	51
<i>TABLE 14 INDUSTRY STRUCTURE: MAJOR COMPETITORS AND MARKETED PRODUCTS</i>	52
MARKET CONCENTRATION AND PRICE SENSITIVITY	52
BARRIERS TO ENTRY	53
Market Saturation and Competitiveness	53
Sales and Marketing Capabilities.....	54
Scientific and Regulatory Challenges in the Development of New Drugs	55
NOTABLE MERGERS AND ACQUISITIONS.....	56
COMPETITIVE FACTORS	57
PRICE	57
PRODUCT EFFICACY AND DOSAGE FREQUENCY	58

DRUG DELIVERY MODE AND CONVENIENCE	58
SAFETY PROFILE	59
MARKETING AND SALES EFFECTIVENESS	60
MARKET CHALLENGES	60
DISEASE UNDERDIAGNOSIS AND UNDERTREATMENT	61
POOR PATIENT ADHERENCE TO MEDICATION THERAPY	61
DRUG REIMBURSEMENT ISSUES	62
INCREASED SCRUTINY IN THE APPROVAL OF NEW DRUGS	62
UNMET MARKET NEEDS	63
IMPROVED ANABOLIC DRUGS	63
DRUGS WITH SUPERIOR EFFICACY	63
IMPROVED SIDE EFFECTS AND SAFETY PROFILE DRUGS	64
IMPROVED DRUG DELIVERY MODALITIES	64
IMPROVED IDENTIFICATION OF PATIENTS REQUIRING THERAPY	65
MARKET TRENDS	65
<i>TABLE 15 MARKET TRENDS IN THE OSTEOPOROSIS MEDICATION MARKET</i>	66
INCREASED PREVALENCE OF OSTEOPOROSIS AND LIFE EXPECTANCY ARE EXPECTED TO DRIVE MARKET GROWTH GLOBALLY	66
ENHANCED PATIENT AND PHYSICIAN AWARENESS IS EXPECTED TO LEAD TO EARLIER DISEASE DIAGNOSIS AND TREATMENT	67
NEW PRODUCT LAUNCHES WITH ENHANCED EFFICACY, CONVENIENCE, AND SAFETY PROFILES ARE EXPECTED TO EXPAND THE MARKET	67
COST CONSTRAINTS TO AFFECT DRUG CHOICE AND REVENUES	68
LOSS OF PATENT PROTECTION FOR MAJOR BLOCKBUSTER DRUGS TO SLOW OVERALL MARKET GROWTH	68
TOTAL MARKET REVENUES AND FORECAST	69
TOTAL MARKET REVENUES	69
<i>TABLE 16 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 (\$ MILLIONS)</i>	69
<i>FIGURE 1 GLOBAL OSTEOPOROSIS DRUG MARKET BY DRUG CLASS, 2008 (%)</i>	70
MARKET SHARES	70
<i>TABLE 17 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	71
<i>FIGURE 2 GLOBAL OSTEOPOROSIS DRUG MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	71

MARKET FORECAST	72
<i>TABLE 18 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, THROUGH 2014 (\$ MILLIONS)</i>	73
<i>FIGURE 3 GLOBAL OSTEOPOROSIS DRUG MARKET BY GEOGRAPHIC REGION, 2007–2014 (\$ MILLIONS)</i>	73
Forecast Assumptions	74
Existing Drug Revenues	74
Patent Expirations of Major Drugs	74
Expected New Drug Launches	75
Expected ... (Continued).....	76
Expected ... (Continued).....	77
CHAPTER SEVEN: MARKETS BY DRUG CLASSES.....	78
BISPHOSPHONATES.....	78
OVERVIEW	78
<i>TABLE 19 BISPHOSPHONATES INDUSTRY STRUCTURE, 2009</i>	79
COMPETITIVE ASPECTS	80
SAFETY CONCERNS	81
MARKET REVENUES AND FORECAST	82
<i>TABLE 20 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY, 2008 (%)</i>	83
<i>FIGURE 4 GLOBAL BISPHOSPHONATES MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	83
<i>TABLE 21 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, THROUGH 2014 (\$ MILLIONS)</i>	84
<i>FIGURE 5 GLOBAL BISPHOSPHONATES MARKET BY DRUG CLASS, 2007–2014 (\$ MILLIONS)</i>	85
PRODUCT ANALYSIS	85
Fosamax.....	85
Competitive Aspects	86
<i>TABLE 22 FOSAMAX ANALYSIS</i>	87
Actonel.....	88
Competitive Aspects	88
Competitive Aspects (Continued)	89
<i>TABLE 23 ACTONEL ANALYSIS</i>	90
Boniva/Bonviva	90
Competitive Aspects	91
<i>TABLE 24 BONIVA/BONVIVA ANALYSIS</i>	92
Reclast/Aclasta.....	93
Competitive Aspects	93
<i>TABLE 25 RECLAST/ACLASTA ANALYSIS</i>	94
SERMS	94
OVERVIEW	94
<i>TABLE 26 SERM INDUSTRY STRUCTURE, 2009</i>	95
COMPETITIVE ASPECTS	96

MARKET REVENUES AND FORECAST	97
<i>TABLE 27 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	97
<i>FIGURE 6 GLOBAL SERM MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	98
<i>TABLE 28 GLOBAL SERM MARKET REVENUES, THROUGH 2014 (\$ MILLIONS)</i>	99
<i>FIGURE 7 GLOBAL SERM MARKET REVENUES, 2007–2014 (\$ MILLIONS)</i>	99
PRODUCTS ANALYSIS	99
Evista	99
Competitive Aspects	100
<i>TABLE 29 EVISTA ANALYSIS</i>	101
PTHS	101
OVERVIEW	101
<i>TABLE 30 PTH DRUG INDUSTRY STRUCTURE, 2009</i>	102
COMPETITIVE ASPECTS	102
Competitive Aspects (Continued).....	103
MARKET REVENUES AND FORECAST	104
<i>TABLE 31 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	104
<i>FIGURE 8 GLOBAL PTH MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	105
<i>TABLE 32 GLOBAL PTH MARKET REVENUES, THROUGH 2014 (\$ MILLIONS)</i>	105
<i>FIGURE 9 GLOBAL PTH MARKET REVENUES, 2007–2014 (\$ MILLIONS)</i>	106
PRODUCT ANALYSIS	106
Forteo/Forsteo.....	106
Competitive Aspects	107
Competitive Aspects (Continued)	108
<i>TABLE 33 FORTEO ANALYSIS</i>	109
CALCITONINS	109
OVERVIEW	109
<i>TABLE 34 CALCITONINS INDUSTRY STRUCTURE, 2009</i>	110
COMPETITIVE ASPECTS	110
Competitive Aspects (Continued).....	111
Competitive Aspects (Continued).....	112
MARKET REVENUES AND FORECAST	113
<i>TABLE 35 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	113
<i>FIGURE 10 GLOBAL CALCITONINS MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	114

<i>TABLE 36 GLOBAL CALCITONINS MARKET, THROUGH 2014 (\$ MILLIONS)</i>	115
<i>FIGURE 11 GLOBAL CALCITONINS MARKET, 2007–2014 (\$ MILLIONS)</i>	115
PRODUCT ANALYSIS	115
Miacalcin/Miacalcic	115
Competitive Aspects	116
<i>TABLE 37 MIACALCIN ANALYSIS</i>	117
DABAS.....	117
OVERVIEW	117
<i>TABLE 38 DABA INDUSTRY STRUCTURE, 2009</i>	118
COMPETITIVE ASPECTS	118
MARKET REVENUES AND FORECAST	119
<i>TABLE 39 GLOBAL DABA MARKET REVENUES, THROUGH 2014 (\$ MILLIONS)</i>	119
<i>FIGURE 12 GLOBAL DABAS MARKET REVENUES, 2007–2014 (\$ MILLIONS)</i>	120
PRODUCT ANALYSIS	120
Protelos	120
Competitive Aspects	120
<i>TABLE 40 PROTELOS ANALYSIS</i>	121
HRT	121
OVERVIEW	121
Overview (Continued).....	122
<i>TABLE 41 SELECTED MARKETED HRT DRUGS, 2009</i>	123
COMPETITIVE ASPECTS	124
MARKET REVENUES AND FORECAST	125
<i>TABLE 42 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	125
<i>FIGURE 13 GLOBAL HRT MARKET SHARES BY COMPANY AND PRODUCT, 2008 (%)</i>	126
<i>TABLE 43 GLOBAL HRT MARKET, THROUGH 2014 (\$ MILLIONS)</i>	126
<i>FIGURE 14 GLOBAL HRT MARKET, 2007–2014 (\$ MILLIONS)</i>	127
PRODUCTS ANALYSIS	127
Premarin Line of Products	127
Competitive Aspects	128
<i>TABLE 44 PREMARIN PRODUCTS LINE ANALYSIS</i>	128
<i>TABLE 44 (CONTINUED)</i>	129
EMERGING DRUG CLASSES	129
OVERVIEW	129
<i>TABLE 45 EMERGING DRUG CLASSES</i>	130
PRODUCT ANALYSIS	130
Prolia	130
Prolia (Continued).....	131

TABLE 46	PROLIA PROFILE.....	132
	Odanacatib	132
TABLE 47	ODANACATIB PROFILE.....	133
	EMERGING DRUG CLASSES FORECAST.....	134
TABLE 48	GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, THROUGH 2014 (\$ MILLIONS).....	134
FIGURE 15	GLOBAL MARKET REVENUES FOR NEW MECHANISM DRUGS, 2007–2014 (\$ MILLIONS).....	134
CHAPTER EIGHT:	MARKETS BY GEOGRAPHICAL REGIONS.....	135
	U.S.	135
	MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS	135
	Market Overview	135
TABLE 49	U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)	135
FIGURE 16	U.S. MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)	136
	Products	136
	Significant Aspects	137
	REVENUE FORECAST	138
TABLE 50	U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, THROUGH 2014 (\$ MILLIONS).....	139
FIGURE 17	U.S. MARKET FOR OSTEOPOROSIS PRESCRIPTION DRUGS, 2007–2014 (\$ MILLIONS).....	139
	EU	140
	MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS	140
	Market Overview	140
TABLE 51	EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)	140
FIGURE 18	EU MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)	141
	Products	141
	Significant Aspects	141
	REVENUE FORECAST.....	142
	Revenue Forecast (Continued).....	143
TABLE 52	EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 (\$ MILLIONS).....	144
FIGURE 19	EU OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007–2014 (\$ MILLIONS)	144
	ROW MARKET	145
	MARKET OVERVIEW: PRODUCTS, SIGNIFICANT ASPECTS	145
	Market Overview	145
TABLE 53	ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)	145

<i>FIGURE 20 ROW MARKET SHARES OF OSTEOPOROSIS PRESCRIPTION DRUGS BY COMPANY AND PRODUCT, 2008 (%)</i>	146
Products	146
Significant Aspects	147
REVENUE FORECAST	148
<i>TABLE 54 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, THROUGH 2014 (\$ MILLIONS)</i>	148
<i>FIGURE 21 ROW OSTEOPOROSIS PRESCRIPTION DRUG MARKET, 2007–2014 (\$ MILLIONS)</i>	149
CHAPTER NINE: PIPELINE REVIEW	150
PIPELINE OVERVIEW	150
PIPELINE OVERVIEW (CONTINUED)	151
RANK-LIGAND INHIBITORS	152
CATHEPSIN K INHIBITORS	152
SCLEROSTIN INHIBITORS	153
CALCILYTICS.....	154
DKK-1 ANTAGONISTS	154
DRUGS FILED FOR REGULATORY APPROVAL	155
PROLIA (DENOSUMAB)	155
CONBRIZA/VIVIAN (BAZEDOXIFENE)	156
FABLYN/OPORIA (LASOFOXIFENE)	156
<i>TABLE 55 OSTEOPOROSIS PIPELINE: DRUGS FILED FOR REGULATORY APPROVAL, 2010</i>	157
DRUGS IN PHASE III CLINICAL TRIALS	157
BISPHOSPHONATES	157
CALCITONINS	158
CATHEPSIN K INHIBITORS	159
SERMS/HRTS	159
PTHs	160
<i>TABLE 56 GLOBAL PHASE III OSTEOPOROSIS PIPELINE, 2010</i>	161
DRUGS IN PHASE II CLINICAL TRIALS	162
BISPHOSPHONATES	162
BONE MORPHOGENETIC PROTEIN.....	162
CALCILYTICS.....	163
CALCITONINS	163
CATHEPSIN K INHIBITORS	163
DABAS	163
PTHs.....	164
SCLEROSTIN INHIBITORS.....	165
<i>TABLE 57 GLOBAL PHASE II OSTEOPOROSIS PIPELINE, 2010</i>	165
<i>TABLE 57 (CONTINUED)</i>	166
DRUGS IN PHASE I CLINICAL TRIALS.....	166
DKK-1 ANTAGONISTS	166
PTHs.....	166

RANK-LIGAND INHIBITORS	167
SCLEROSTIN INHIBITORS.....	167
SRC KINASE INHIBITORS.....	168
<i>TABLE 58 GLOBAL PHASE I OSTEOPOROSIS PIPELINE, 2010.....</i>	<i>168</i>
CHAPTER TEN: COMPANY PROFILES	169
ABLYNX NV	169
AEGIS THERAPEUTICS, LLC.....	169
AMGEN, INC.	170
BONE MEDICAL, LTD.	171
CHUGAI PHARMACEUTICAL	171
DAIICHI SANKYO	172
EFFRX, INC.....	172
ELI LILLY	173
EMISPHERE TECHNOLOGIES	174
GLAXO WELLCOME U.K., LTD.....	174
GLAXOSMITHKLINE U.S.....	175
GREEN CROSS CORP.	176
LES LABORATOIRES SERVIER.....	176
MERCK & CO., INC.	177
MERRION PHARMACEUTICALS.....	177
NOVARTIS PHARMA	178
NOVARTIS CORP.....	178
NOVARTIS PHARMACEUTICALS CORP.....	178
NOVO NORDISK.....	179
NPS PHARMACEUTICALS.....	180
NYCOMED INTERNATIONAL MANAGEMENT GMBH	180
OSTEOLOGIX.....	181
PFIZER, INC.....	182
PROXIMA CONCEPTS	182
RADIUS HEALTH	183
RANBAXY LABORATORIES.....	184
ROCHE.....	184
HOFFMANN- LA ROCHE PHARMACEUTICALS.....	184
SANOFI-AVENTIS	185
SANOFI-AVENTIS U.S.	185
TAISHO PHARMACEUTICAL	186
TEIJIN PHARMA, LTD.....	186
TEIJIN AMERICA, INC.	186
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	187
TEVA PHARMACEUTICALS USA.....	187
TRANSPHARMA MEDICAL, LTD.....	188
UNIGENE LABORATORIES.....	188
WARNER CHILCOTT, PLC.....	189
ZELOS THERAPEUTICS, INC.....	190

ZOSANO PHARMA	190
CHAPTER ELEVEN: NASCENT PATENT APPLICATION ACTIVITY	191
NASCENT PATENT APPLICATION ACTIVITY	191
NASCENT PATENT APPLICATION ... (CONTINUED)	192
NASCENT PATENT APPLICATION ... (CONTINUED)	193
NASCENT PATENT APPLICATION ... (CONTINUED)	194
NASCENT PATENT APPLICATION ... (CONTINUED)	195
NASCENT PATENT APPLICATION ... (CONTINUED)	196
NASCENT PATENT APPLICATION ... (CONTINUED)	197
NASCENT PATENT APPLICATION ... (CONTINUED)	198